During the opening segment of this panel discussion about recent advances and pharmacoeconomic considerations in the clinical management of Castration-Resistant Prostate Cancer (CRPC), discussion moderator Raoul S. Concepcion, MD, is joined by expert panelists David Crawford, MD, Jeffrey D. Dunn, PharmD, MBA, Michael Kolodziej, MD, and David Quinn, MD.
After the panelists briefly introduce themselves and explain their relationships to medical oncology, Dr Concepcion cites important statistics about the economic and clinical burden of CRPC.
Dr Quinn reviews the treatment landscape for CRPC and explains how a paradigm shift in the US Food and Drug Administration’s approval of agents to treat CRPC has improved the disease’s outlook.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Demographic Disparities in Video Visit Telemetry: Understanding Telemedicine Utilization
March 7th 2025A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.
Read More